• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (PubMed=8557231).
  

PubMed=2227544; DOI=10.1016/0090-8258(90)90068-V
Bonavida B., Tsuchitani T., Zighelboim J., Berek J.S.
Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Gynecol. Oncol. 38:333-339(1990)

PubMed=1918981; DOI=10.4049/jimmunol.147.8.2609
Morimoto H., Safrit J.T., Bonavida B.
Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.
J. Immunol. 147:2609-2616(1991)

PubMed=8557231; DOI=10.1006/gyno.1996.0014
Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.
p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Gynecol. Oncol. 60:72-80(1996)

PubMed=9554442; DOI=10.1093/jnci/90.8.597
Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.
Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
J. Natl. Cancer Inst. 90:597-605(1998)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)